Genomic Health Announces Results of Oncotype DX® Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology

    Genomic Health Announces Results of Oncotype DX® Colon Cancer Studies
   Presented at 2014 American Society of Clinical Oncology Gastrointestinal
                          Cancer (ASCO GI) Symposium

New data show real-life impact of Oncotype DX on treatment decisions,
underscore clinical validity and utility of the test

PR Newswire

REDWOOD CITY, Calif., Jan. 29, 2014

REDWOOD CITY, Calif., Jan. 29, 2014 /PRNewswire/ -- Genomic Health, Inc.
(Nasdaq: GHDX) today announced results from the Oncotype DX^® colon cancer
test studies that were recently presented at the 2014 American Society of
Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI). Presentations
highlighted the robust body of clinical evidence for the Oncotype DX colon
cancer test and its real-life impact on patient and physician treatment
decisions, underscoring the practice-changing value of this test.


Prospective study demonstrated real-life impact on physician and patient
treatment decisions

Through an analysis of physician recommendations and patient treatment
preferences before and after receiving the Oncotype DX colon cancer test
results, this study demonstrated that the test greatly increased concordance
between physician and patient treatment choice (from 66 percent to 96
percent). Furthermore, the evaluation showed that the quantitative
information provided by the Recurrence Score^® result influenced a majority of
patients' treatment decisions (85 percent) and physicians' treatment
recommendations (69 percent), and it increased physicians' confidence in their
own recommendations (84 percent). Patients' anxiety was also significantly
reduced, which may improve adherence to their treatment plan and ultimately
lead to better health outcomes.

"The additional information provided by the Oncotype DX test enables me and my
patients to make better informed decisions about their individual treatment,"
said Steven Alberts, M.D., chair of the Division of Medical Oncology at Mayo
Clinic Cancer Center, Rochester, Minn. "The test also helps patients gain
greater confidence in the prescribed course of treatment, which is key to
achieving optimal health results."

Robust data shows Oncotype DX meets tumor marker level I evidence for clinical
use in colon cancer

The review of four validation studies of the Oncotype DX colon cancer test,
which included a total of 3,315 patients with early stage colon cancer,
consistently demonstrated a significant association (p<0.05) between the test
results and recurrence risk and cancer-specific survival. Based on these
results, the Oncotype DX colon cancer test meets level I evidence criteria,
underscoring the test's clinical value beyond traditional clinicopathologic
variables such as age, tumor size, tumor grade, number of nodes examined or
evidence of lymphovascular invasion. Additionally, three decision impact
studies with a total of 502 patients showed that the test changed treatment
recommendations in 29 to 45 percent of stage II colon cancer cases, leading to
a net reduction in adjuvant chemotherapy use. This analysis included
previously-presented positive results by Partnership for Health Analytic
Research, a multi-center study conducted in collaboration with the Mayo Clinic
Cancer Research Consortium and a study conducted by Clalit Health Services in

"Over the last decade, Genomic Health has demonstrated that the rigorous
validation of genomic information can transform cancer treatment," said Phil
Febbo, M.D., chief medical officer, Genomic Health. "As we mark the 10^th
anniversary of the first Oncotype DX test, we continue to apply our
world-class science to usher genomic data into practice-changing results for
patients living with breast, colon, and prostate cancer worldwide."

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of
genomic-based diagnostic tests that address both the overtreatment and optimal
treatment of early stage cancer, one of the greatest issues in healthcare
today. The company is applying its world-class scientific and commercial
expertise and infrastructure to lead the translation of massive amounts of
genomic datainto clinically-actionable results for treatment planning
throughout the cancer patient's journey, from screening and surveillance,
through diagnosis, treatment selection and monitoring. Genomic Health's lead
product, the Oncotype DX® breast cancer test, has been shown to predict the
likelihood of chemotherapy benefit as well as recurrence in invasive breast
cancer and has been shown to predict the likelihood of recurrence in ductal
carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic
Health provides the Oncotype DX colon cancer test, the first multi-gene
expression test developed for the assessment of risk of recurrence in patients
with stage II and stage III disease, and the Oncotype DX prostate cancer test,
which predicts disease aggressiveness in men with low risk disease. As of
September 30, 2013, more than 19,000 physicians in over 70 countries had
ordered nearly 400,000 Oncotype DX tests. The company is based in Redwood
City, California with European headquarters in Geneva, Switzerland. For more
information, please visit, and follow the company on
Twitter: @GenomicHealth. To learn more about OncotypeDX tests, visit:, and

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the potential of the company's colon cancer test to change medical
practice; the ability of test to influence physicians treatment
recommendations and patients treatment decisions and potentially improve
adherence to selected treatment plan; the ability of the test to reduce the
use of chemotherapy and the direct medical costs associated with treating
colon cancer for patients with stage II colon cancer; the ability of the
company to develop additional tests in the future; the size of markets and
demand for the company's tests; and the company's ability to commercialize new
tests and expand into new markets domestically and internationally.
Forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to: the applicability of study
results to clinical practice; the timing and results of future studies or
clinical trials; the focus and attributes of the company's product pipeline;
the ability of the company to develop additional tests in the future; and the
ability of the company's currently offered tests, including its colon cancer
test, and any potential tests the company may develop to optimize cancer
treatment; the company's ability to increase usage of its tests; the risk that
the company may not obtain or maintain sufficient levels of reimbursement,
domestically or abroad, for its existing tests and any future tests it may
develop; the risks and uncertainties associated with regulation of the
company's tests by the FDA and other regulatory organizations; the company's
ability to compete against third parties; and the other risks set forth in the
company's filings with the Securities and Exchange Commission, including the
risks set forth in the company's Quarterly Report on Form 10-Q for the quarter
ended September 30, 2013. These forward- looking statements speak only as of
the date hereof. Genomic Health disclaims any obligation to update these
forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and
DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their respective

SOURCE Genomic Health, Inc.

Contact: Investors: Dean Schorno, Genomic Health, 650-569-2281,, Media: Victoria Steiner, Genomic Health,
Press spacebar to pause and continue. Press esc to stop.